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Abstract
Background: Interferon (IFN)-α is considered a key modulator of immunopathological processes through a
signature-specific activation of mononuclear phagocytes (MPs). This study utilized global transcript analysis to
characterize the effects of the entire type I IFN family in comparison to a broad panel of other cytokines on MP
previously exposed to Lipopolysaccharide (LPS) stimulation in vitro.
Results: Immature peripheral blood CD14+ MPs were stimulated with LPS and 1 hour later with 42 separate
soluble factors including cytokines, chemokines, interleukins, growth factors and IFNs. Gene expression profiling
of MPs was analyzed 4 and 9 hours after cytokine stimulation. Four hours after stimulation, the transcriptional
analysis of MPs revealed two main classes of cytokines: one associated with the alternative and the other with the
classical pathway of MP activation without a clear polarization of type I IFNs effects. In contrast, after 9 hours of
stimulation most type I IFN isoforms induced a characteristic and unique transcriptional pattern separate from
other cytokines. These "signature" IFNs included; IFN-β, IFN-α2b/α2, IFN-αI, IFN-α2, IFN-αC, IFN-αJ1, IFN-
αH2, and INF-α4B and induced the over-expression of 44 genes, all of which had known functional relationships
with IFN such as myxovirus resistance (Mx)-1, Mx-2, and interferon-induced hepatitis C-associated microtubular
aggregation protein. A second group of type I IFNs segregated separately and in closer association with the type
II IFN-γ. The phylogenetic relationship of amino acid sequences among type I IFNs did not explain their sub-
classification, although differences at positions 94 through 109 and 175 through 189 were present between the
signature and other IFNs.
Conclusion: Seven IFN-α isoforms and IFN-β participate in the late phase polarization of MPs conditioned by
LPS. This information broadens the previous view of the central role played by IFN-α in autoimmunity and tumor
rejection by including and/or excluding an array of related factors likely to be heterogeneously expressed by
distinct sub-populations of individuals in sickness or in response to biological therapy.
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Background
It has been proposed recently that autoimmunity or, more
generally, immunity is driven by a dynamic system bal-
ancing opposite vectors represented by type one interfer-
ons (IFNs) in one direction and tumor necrosis factor
(TNF) in the other [1]. This dichotomy is mediated
through divergent activation of mononuclear phagocytes
(MPs) by the two cytokine families resulting in specific
signatures of gene expression that are characteristic of dis-
tinct autoimmune pathologies such as systemic lupus ery-
thematosus (SLE, IFN-α/β) or rheumatoid arthritis (TNF)
[1-3].
Interestingly, although type I IFN signatures are consist-
ently observed in patients with SLE, only a fraction of
them demonstrate elevated IFN serum protein levels [2].
Therefore, it is possible that testing methods may not
detect all the IFN species that might circulate in the blood
and which may yield similar biological effects. For this
reason, we evaluated the effect of a panel of related type I
IFN molecules in modulating the transcriptional profile
of MPs exposed to lipopolysacaride (LPS) according to a
previously described experimental model [4]. The molec-
ular signatures of type I IFNs were compared with those of
IFN-γ, TNF-α and TNF-β as well as a comprehensive panel
of other cytokines to characterize the specificity of IFN
polarization of MPs in the context of an extended cytokine
network.
Indeed, MPs play a critical role in acute and chronic
inflammation performing diverse functions in different
stages of activation. MPs recruit and activate immune
effector cells or they may down-regulate the inflammatory
process to contain collateral damage [5]. Pro-inflamma-
tory MPs, known as type 1 or M1 MPs, function as true
antigen presenting cells that recruit and activate immune
effector cells [6,7]. MP that enhance tissue repair, stimu-
late angiogenesis, and contain collateral damage through
reduced inflammation are known as type 2, or M2 MPs
[8,9]. Type 2 mononuclear phagocytes can be further cat-
egorized as M2 a, b, c [10] suggesting a continuous spec-
trum of MP activation.
Many factors may influence the differentiation of imma-
ture MPs toward a polarized M1 or M2 phenotype along
the classical or the alternative pathway of transcriptional
activation [9]. Theoretically, the in vivo functional pheno-
type of MPs along each of these pathways is dependent on
the environment, since foreign products (microbial prod-
ucts) and endogenous cytokines modulate their activation
and maturation [11]. MPs are capable of tailoring their
response to specific microbes and microbial products as
demonstrated by the display of a distinct gene expression
profile upon stimulation with different pathogen prod-
ucts [11]. The effects of different cytokines and other bio-
active soluble factors on MPs are also variable.
Stimulation of MPs with interferon-γ (IFN-γ) alone or
with lipopolysacaride (LPS) plus IFN-γ, CD40L, and Flt-3
ligand (FLT3-L) yields M1 MPs. Treatment of MPs with IL-
4 and IL-13 induces a M2 MP phentotype.
Changes in MPs following microbial stimulation do not
occur as a single event over a brief period of time but in
waves each lasting several hours. A comparison of MPs
stimulated with 3 different microbes, E. coli, C. albicans
and influenza found that gene expression was most rap-
idly induced by E. coli and most slowly by influenza. The
gene expression profiles induced by these three microbes
continued to change for more than 24 hours [11].
We have found that cytokines have a marked affect on
LPS-stimulated MPs [7]. Immature CD14+ peripheral
blood MPs were stimulated with LPS and one hour later
they were treated separately with 42 different cytokines.
After 4 hours, the MPs were analyzed by gene expression
profiling using a 17 K cDNA chip. LPS-stimulation alone
induced a gene expression profile typical of the classical
pathway of MP activation, but which was markedly
altered by additional cytokine stimulation. Hierarchical
clustering of gene expression profiles of LPS-stimulated
MPs treated with 42 factors for four hours revealed two
main groups of cytokines. One group included IL-4, IL-13,
TGF-α, TGF-β, and VEGF and represented the alternative
pathway of MP activation. A second group included IFN-
β, IFN-γ, CD40L, and FLT-3L generally associated with the
classical pathway. Some cytokines such as IL-10, IL-1β, IL-
15, IFN-αA and IFN-α2b did not separate into either of
the two classes [4].
Interestingly, 4 hours after cytokine exposure, type I IFNs
did not display similarities in MP transcriptional activa-
tion among themselves. Instead, the various IFN family
members were scattered among the different cytokine sub
classifications. This finding suggested that IFN polariza-
tion of MP activation following LPS exposure is a delayed
event. In this study, therefore, we present the gene profil-
ing of LPS-conditioned MPs 9 hours after exposure to 42
different cytokines as previously reported for the 4 hour
time point [4]. Prolonged exposure (9 hours) to these bio-
active factors revealed a unique polarization of MP matu-
ration induced by most (but not all) members of the type
I IFN family and singled out this group of factors for its
ability to induce a distinctive MP gene expression profile.
Materials and methods
MP separation and FACS staining
Peripheral blood mononuclear cells (PBMC) from an
HLA-A*0201 positive healthy Caucasian male donor age
35 were collected by lymph apheresis at the Department
of Transfusion Medicine, NIH. PBMC were isolated byJournal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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Ficoll gradient separation and frozen until analysis. After
thawing, PBMC were kept overnight in 175 cm2 tissue cul-
ture flasks (Costar, Cambridge, MA) in complete medium
(CM) consisting of Iscove's medium (Biofluids, Rockville,
MD) supplemented with 10% heat-inactivated human
AB-serum (Gemini Bioproducts, Inc, Calabasas, CA), 10
mM hepes buffer (Cellgro, Mediatech, Inc. Herndon, VA),
0.03% L-glutamine (Biofluids), 100 U/ml Penicillin/
Streptomycin (Biofluids), 10 µg/ml Ciprofloxacin (Bayer,
West Haven, CT), and 0.5 mg/ml amphotericin B (Bioflu-
ids). Adherent and non-adherent cells were gently
removed from the flask and centrifugated. MP were sepa-
rated by negative selection using the MP isolation kit and
an autoMACS system (both Miltenyi, Bergisch Gladbach,
Germany). Before and after separation cells were stained
with anti-CD14-FITC (Becton Dickinson, San Diego, CA),
and analyzed using a FACScalibur flow cytometer and
CellQuest software (Becton Dickinson).
Stimulation of MP, RNA isolation
Negatively selected CD14+ cells were washed twice with
serum free OPTI-MEM (OM) medium (GIBCO BRL) pre-
pared similarly to CM. The final cell population which
contained > 90% CD14+ cells was then seeded at the con-
centration of 1 × 106 / ml in 10 ml OM in 25 cm2 flasks
(Falcon, Franklin Lakes, NJ) and stimulated with 5 µg/ml
LPS (SIGMA St. Louis, MO) for one hour. No LPS was
added to the non-stimulation control flask. After one
hour, 42 cytokines, chemokines and soluble factors were
added individually to the MP suspensions (IL-1α, IFN-αC,
IFN-αJ1, IL-13, IFN-α4B, MIP-1β, IFN-αG, IL-12, IL-5, IL-
4, VEGF, TGFβ, IL-8, IFN-α1, MIP-4 (Parc), Rantes, IFN-
αWA, TGFα, IFN-γ, IFN-α2, BCA-1, IFN-αF2, IL-2, Flt-3
Ligand, MIP 1α, IFN-αK, IL-6, IFN-β, IFN-αH2, IFN-αβ2,
CD40L, IL-3, Tarc, TNF-α, IFN-α2b, IL-10, Aldara, IL-
1 IL-15, IFN- A, TNF- GM-CSF) [4]. Nine hours after
LPS stimulation, MP were harvested, washed twice in PBS,
and lysed for RNA isolation using 700 µl RNeasy lysis
buffer per 25 cm2 flask, according to the manufacturer's
protocol.
Probe preparation, amplification, and hybridization to 
microarrays
Total RNA was isolated using RNeasy minikits (Qiagen).
Amplified antisense RNA (aRNA) was prepared from total
RNA (0.5–3 µg) according the protocol previously
described by us [12,13]. Test samples were labeled with
Cy5-dUTP (Amersham, Piscataway, NJ) while the refer-
ence sample (pooled normal donor PBMC) was labeled
with Cy3-dUTP. Test-reference sample pairs were mixed
and co-hybridized to 17 K-cDNA microarrays.
Microarrays and statistical analyses
Hybridized arrays were scanned at 10-µm resolution on a
GenePix 4000 scanner (Axon Instruments, Union City,
CA) at variable PMT voltage to obtain maximal signal
intensities with < 1% probe saturation. Resulting tiff
images were analyzed via ArraySuite software (National
Human Genome Research Institute, Bethesda, MD). Data
were further analyzed using Cluster and Tree View soft-
ware [14] and Partek Pro software (Partek Inc., St Charles,
MO). The global gene expression profiling of 9 hour
treated and untreated MP consisted of 49 experimental
samples. Subsequent low stringency filtering (80% gene
presence across all experiments and removal of genes that
did not have at least in 1 of the samples a Log2 = 2; 4 ratio)
selected 2,063 genes for further analysis. Clustering of
experimental samples according to Eisen et al. was based
on these genes. Gene ratios were average corrected across
experimental samples and displayed according to the cen-
tral method for display using a normalization factor as
recommended by Ross [15].
Results
Genes differentially expressed 9 hours after LPS and 
Cytokine Stimulation
We have previously shown that the transcriptional profile
of MPs stimulated by LPS and subjected for 4 hours to dis-
tinct cytokine stimulation can be polarized into two
major subgroups and an third intermediate subgroup
according to the type of cytokine used in culture [4]. IFN-
γ stimulation induced transcriptional changes that are
consistent with its pro-inflammatory activity and with the
type I pathway of MP activation [10]. After 4 hours type I
IFNs demonstrated a variety of individual transcriptional
profiles and no type I IFN-specific signatures could be
identified. On the contrary, in the present analysis, we
observed that 9 hours after stimulation a number of type
I IFNs congregated within a single cluster that was charac-
terized by molecular signatures unique to these cytokines
and was responsible for a unique MP polarization
response. This pattern of IFN-induced polarization was
identified as follows: unsupervised hierarchical clustering
analysis was applied to the global data set of MPs treated
separately with 42 cytokines for 9 hours after LPS stimula-
tion. The data set was filtered to sort genes that were
expressed in at least 80% of samples and whose expres-
sion was increased 3 or more fold in at least one sample.
Filtering yielded 2,063 genes that would be most inform-
ative among the 17 K gene pool.
Cytokine treatments segregated into five groups (Figure
1). One group included cytokines best classified as those
that act through the classical pathway of MP activation
such as IFN-γ, TNF-α, IL-3, IL-6, GM-CSF, and CD40L
(Red bar, Figure 1). These cytokines were similarly classi-
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Unsupervised clustering of LPS-stimulated CD14+ MP exposed to distinct cytokine treatments Figure 1
Unsupervised clustering of LPS-stimulated CD14+ MP exposed to distinct cytokine treatments. CD14+ MP were 
stimulated in parallel with LPS and exposed after 1 hour to 42 individual cytokines. Antisense RNA obtained 9 hours following 
LPS stimulation, was hybridized to custom made 17 k cDNA arrays. Unsupervised Eisen [20] clustering was applied to the 
complete, unfiltered data set of 98 experiments. A375 is a melanoma cell line that was used for quality control alternating con-
ventional (Cy5, red) or reciprocal (Cy3, green) labeling every 25 experiments as previously described [18]. A total of 2063 
genes were analyzed. These genes were obtained by filtering the 16,000 genes and analyzing only those present in greater than 
80% of samples and with at least one observation greater than 2 logs. The expression of each gene was average corrected 
among the cytokines.Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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Table 1: 44 Signature Genes that are Interferon Related






SP110 nuclear body protein Interferon-induced protein 41/75 yes yes 16
C1Orf29 Unknown yes yes none
ISG20 IFN stimulated genes HEM45 yes yes 17–18
TNFSF13B TFN superfamily BAFF BAFF BLYS HGNC:13472 TALL-1 THANK 
TNFSF20 ZTNF4 (L
yes yes 19
ITGA5 Integrin-alpha 5 (receptor for fibrinogen 
and fibronectin)
CD49e, FNRA, VLA5A, fibronectin receptor (alpha 
subunit), integrin alpha 5
yes yes 20
Mx1 Mixovirus resistence yes no 21
IFRG28 IFN responsive, potential type III 
membrane protein
yes no none
CXCL10 CXC family C7, IFI10, INP10, IP-10, SCYB10, crg-2, gIP-10, mob-
1, chemokine (C-X-C motif) ligand 10, gamma IP10
yes yes 22,23
OAS2 2'5'OAS 2 yes yes 24
OAS1 2'5'OAS 1 yes yes 25
TRIM22 STAF 50 GPSTAF50, RNF94, STAF50-PEN, Stimulated Trans-
Acting Factor
yes yes 25,26
UBE2L6 Ubiquitin conjugated enzyme MGC40331, RIG-B, UBCH8, retinoic acid induced 
gene B protein, ubiquitin carrier protein, ubiquitin-
conjugating enzyme E2L 6, ubiquitin-protein ligase, 
Ubiquitin-conjugating enzyme
yes yes 27
Ly6E Lymphocyte antigen complex LY6, RIG-E, RIGE, SCA-2, SCA2, TSA-1 yes yes 28
IFITM3 IFN-induced transmembran protein 1-8U yes no 29,30
GMPR Guanosine monophosp reductase Catalyzes the irreversible NADPH-dependent 
deamination of GMP to IMP
yes no none
PSME2 PA28 Proteasome subunit PA28B, PA28beta, REGbeta, 11S regulator complex 
beta subunit, MCP activator
yes yes 31, 32
PSMB9 Proteasome subunit LMP2, RING12 yes yes 32
GBP1 Binds GTP, GDP and GMP Interferon-induced guanylate-binding protein 1 yes yes 33
NUP155 nucleoporin KIAA0791, N155 yes yes none
CIG5 antiviral protein induced by CMV vig1, Viperin yes yes 34
LAP3 Signal transducer HGNC:8843, LAP, LAPEP, PEPS yes yes 35
Stat1 Transcription factor that binds to the ISRE 
and GAS elements
ISGF-3, STAT91 yes yes 36
PRIC 285 helicase FLJ00244, KIAA1769 yes yes none
TRAF5 adapter protein and signal transducer MGC:39780, RNF8 yes yes none
KIAA1268 unknown yes yes none
NTRK2 tyrosine kinases receptor TRKB yes yes 37
ZC3HDC
1
zinc finger CCCH-type domain yes yes none
BST2 bone marrow stromal antigen yes yes none
LIPC lipase, hepatic HL, HTGL, LIPH, lipase hepatic yes no none
IFI44 interferon-induced, hepatitis C-associated 
microtubular aggregate protein
MTAP44 yes yes 38
IFIT2 IFN-α inducible protein G10P2, GARG-39, IFI-54, IFI54, ISG-54K, cig42, 
Interferon alpha-inducible protein
yes yes 39, 40
G1P2 IFN-α inducible protein, Ubiquitin cross-
reactive protein precursor
IFI15, ISG15, UCRP yes yes 27
G1P3 IFN-α inducible protein 6–16, IFI616, interferon, alpha-inducible protein yes no 41
Mx2 myxo resistance yes no 21
IFIT1 IFN-α inducible protein G10P1, GARG-16, IFI-56, IFI56, IFNAI1, RNM561 yes no 42
PRKR Interferon-induced, double-stranded 
RNA-activated protein kinase
EIF2AK1, PKR, interferon-inducible elF2alpha kinase yes yes 43
OAS3 2'5'OAS 3 p100, 2'-5'-oligoadenylate synthetase 3 yes yes 24
LOC1296
07




ubiquitin-protein ligase, regulation of cyclin 
dependent protein kinase activity
CEBP1, HECT E3 ubiquitin ligase yes no 44
DXD58 Retinoic acid-inducible gene RIG-I, DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 yes no 45Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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Since most though not all the cytokines in this group are
recognized to act through the classical pathway of MP acti-
vation, this group was referred to as the "classical-like"
group. Interestingly, this group included not only the type
II IFN-γ but other type I IFNs such as IFN-αK and IFN-
αWA. This observation suggested that these type I IFNs
have similarities in the transcriptional activation of MPs
with type II IFNs. Another cluster included cytokines that
are characteristically included in the alternative pathway
of MP activation such as IL-13, VEGF and TGF-α and it
was referred to as the "alternative-like" group 1 (Black
bar, Figure 1). On visual inspection this group displays a
transcriptional profile opposite to the classical group. This
group also included type I IFNs such as IFN-αB2 and IFN-
αF or IFN-α21). A third group contained several cytokines
that also activate MPs via the alternative pathway includ-
ing IL-4, MIP-1α, and MIP-1β and was referred to as alter-
native-like group 2(Green bar, Figure 1). This group was
most distant in transcriptional profile from all other
groups and was separated from them by the transcrip-
tional profile of MPs stimulated with oligonucleotides
containing a unmethylated deoxycytosine-deoxyguanos-
ine (CpG) motifs mixture (CpG mix type K) (Grey bar,
Figure 1) or had not been exposed to any soluble factors
and, therefore, was representative of the transcriptional
profile of MPs in culture. Thus, this group most likely rep-
resented the most divergent example of alternative MP
activation 9 hours after stimulation. However, even on
visual inspection, the alternative-like group 2 displays a
transcriptional pattern similar to the alternative-like
group 1 with most genes co-coordinately expressed
between them (Figure 1).
A fourth cluster included a variety of cytokines whose
effect on MPs could not be precisely categorized. How-
ever, on visual inspection this group approximated the
classical-like group. This group comprised IL-5, IL-10, IL-
12 and TGF-β and was called "classical-like group 2"The
fifth and most relevant to this study was a cluster we called
"signature IFNs", that included only type I IFNs such as:
IFN-β, IFN-α2/ α2, IFN-αI, IFN-α2, IFN-αC, IFN-αJ1,
IFN-αH2, and IFN-α4B. This grouping of type I IFN
strongly suggested an IFN-specific pathway of MP polari-
zation in the late phase of their transcriptional response to
LPS.
Overall, 15 IFNs were tested, 13 IFN-α's, IFN-β and IFN-γ.
The IFNs not included among the eight present in the fifth
cluster included IFN-γ and IFN-αA, IFN-αG, IFN-αK, IFN-
αWA, IFN-αF, IFN-αB2. IFN-αF and IFN-αB2 clustered
with the Alternative-like group 1 group, while IFN-αA and
IFN-αG with the Alternative-like group 2. IFN-αK, IFN-
αWA, and IFN-γ clustered with the classical cytokines.
Interestingly, the global transcript profile of the 8 type I
signature IFNs was opposite for a large number of genes to
that of classical-like cytokines which included TNF-α sug-
gesting that, indeed, type I IFNs represent a distinct bio-
logical vector of MP maturation.
Two functional signatures appeared to be particularly
restricted to signature IFNs. These two signatures included
52 cDNA clones representing 51 genes. In one signature
19 clones represented 18 genes and in the other and 33
clones represented 33 genes. Forty four of the 51 signature
genes were unique. Duplicate copies of 7 genes were
among 51 genes. These 44 genes characterized the unique
transcriptional profile of type I IFN polarized MPs (Figure
2). All 44 signature genes were previously known to be
associated with IFN function [16-49] (Table 1). Among
them were included myxovirus resistance (Mx)-1, Mx-2,
interferon-induced hepatitis C-associated microtubular
aggregation protein, 2',5'-oligoadenylate synthetase 1
(OAS1), OAS2, and OAS3, vipirin (CIG5), IFN regulatory
factor 7 (IRF-7), and lymphocyte antigen 6 complex
(LY6E), Interferon stimulated gene (ISG20), Interferon
responsive protein (IFRG28), Interferon induced trans-
membrane protein 3 (I-8D) (IFITM3), Interferon induced
protein with tetratricopeptide 1 (IFIT1), Interferon
induced protein with tetratricopeptide 2 (IFIT2), Inter-
feron-alpha inducible protein (GIP2), Interferon-alpha
inducible protein (GIP3), Protein kinase, interferon-
inducible double stranded RNA activated protein kinase
(PRKR), and Signal transducer and activator of transcrip-
tion 1 (STAT1). Seven of these genes were duplicated in
the array, nuclear body protein (SP110), OAS1, OAS3,
ISG20, ubiquitin conjugated enzyme E2L6 (UBE2LB),
PA28 proteasome subunit (PSME2), and IFIT2, and both
USP18 ubiquitin specific protease 18 ISG43, UBP43, ubiquitin specific protease 18 yes no 46, 47
PRSS21 protease serine, Could regulate 
proteolytic events associated with 
testicular germ cell maturation.
ESP-1, TEST1, testisin yes no none
IRF7 IFN regulatory factor 7 yes yes 48
PLA2G4B phospholipase A2 CPLA2-BETA, HsT16992, PLA2G4B protein yes yes 49
* Interferon γ only
Table 1: 44 Signature Genes that are Interferon Related (Continued)
 bJournal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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copies of the seven genes were among the 52 cDNA
clones. It is important to note that the non-signature IFNs
demonstrated nearly identical expression of these genes
while none of the other cytokine studied expressed them;
underlining the selectivity of this expression pattern to
type I IFNs with some overlap with IFN-γ.
Specificity of type I IFN signatures
To determine whether the MP genes included in the IFN-
specific signatures were specifically differentially
expressed by all IFNs compared with other cytokines, we
regrouped the various cytokine treatments according to
hierarchical clustering analysis based on only the 44 sig-
nature genes (Figure 3). Indeed, the expression of all of
the signature genes was shared by all type I IFNs and was
partially shared by IFN-γ, which clustered in between type
I IFNs and the other cytokines. The signature IFNs
remained in a single group, but this group also included
IFN-αA and IFN-αK. Thus, the differences in the transcrip-
tional profile of MPs treated by distinct types of type I
IFNs were not due to different activation of IFN-specific
genes but rather by additional effects that distinct IFNs
have on MP activation
The genes overexpressed by LPS-stimulated MPs treated by 8 type I IFNs Figure 2
The genes overexpressed by LPS-stimulated MPs treated by 8 type I IFNs. Unsupervised hierarchical clustering was 
applied to LPS-stimulated CD14+ MP treated for 9 hours with 42 individual cytokines. FN-β and seven αFNs were clustered 
into a separate group, the signature IFNs. These IFNs were characterized by the marked overexpression of two groups of 
genes shown. The genes were overexpressed by the eight IFNs and were identified by visual inspection. The analysis was pre-
formed on the same 2063 genes used in figure 1.Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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To determine the genes responsible for the differentiation
between signature and non-signature IFNs, we identified
genes statistically differentially expressed between the two
groups. The expression of 83 genes differed significantly
between the signature and non-signature IFNs (unpaired t
test p2-value < 0.05) (Figure 4). The signature IFNs
remained in a single group, but this group also included
IFN-αWA and IFN-αK. The expression of a specific set of
genes in the node spanning from the CD164 antigen to
protein-kinase, interferon-inducible repressor (PRKRIR)
resulted in the grouping of IFN-αWA and IFN-αK with the
signature IFNs.
By using a data base for annotation visualization and inte-
grated discovery http://david.niaid.nih.gov/david/
upload.asp, genes differentially expressed between signa-
ture-and non-signature-IFNs were categorized according
to specific cellular and molecular functions. Sixteen func-
tional groups each containing at least 3 representative
genes belonging to a particular biological process were
selected: 1) Metabolism/protein metabolism; 2) Catalytic
activity/ hydrolase activity; 3) Cell proliferation; 4) Cell
growth and maintanance; 5) Cell cycle; 6) Regulation of
transcription; 7) Nuclear binding; 8) Nucleobase/ nucleo-
side and nucleic acid metabolism; 9) Signal transducer
activity; 10) Immune response/defence; 11) Cell
adhesion; 12) Development; 13) biosynthesis/regulation
Clustering of all 15 IFNs among the 54 genes overexpressed by LPS-stimulated MP treated with the eight signature IFNs Figure 3
Clustering of all 15 IFNs among the 54 genes overexpressed by LPS-stimulated MP treated with the eight sig-
nature IFNs. Hierarchical clustering was applied to LPS-stimulated CD14+ MP treated for 9 hours with 42 individual 
cytokines. The analysis was limited to the 52 genes overexpressed by signature IFNs.Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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Selection and clustering of genes differently expressed among LPS-stimulated MPs treated with the signature IFNs and non-sig- nature IFNs Figure 4
Selection and clustering of genes differently expressed among LPS-stimulated MPs treated with the signature 
IFNs and non-signature IFNs. Unsupervised hierarchical clustering was applied to LPS-stimulated CD14+ MP treated for 9 
hours with the IFNs. The analysis was restricted to genes that were differentially expressed between the signature and non-sig-
nature INFs (p < 0.05), but the 52 genes markedly overexpressed by LPS-stimulated MPs treated with the signature IFNs were 
excluded from the analysis. The signature IFNs are shown in blue and the non-signature IFNs are shown in red.Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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Table 2: Functional grouping of genes differentially expressed between signature and non-signature IFNs
GENENAME GENE DEESCRIPTION LOCUSLINK CLASSIFICATIONS UNIQID LOCUSLINK
1)Metabolism/protein metabolism
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
ATP binding; DNA damage response, signal transduction resulting in 
cell cycle arrest; MAP kinase kinase kinase activity; activation of 
JUNK; activation of MAP/ERK kinase kinase; activation of MAPKK; 
cell cycle arrest; cell death; cell differentiation; cell proliferation; 
cellular_component unknown; protein amino acid phosphorylation; 
protein serine/threonine kinase activity; protein-tyrosine kinase 
activity; response to radiation; response to stress; transferase 
activity
Hs.115175 51776
MMP9 matrix metalloproteinase 9 
(gelatinase B, 92 kDa 
gelatinase, 92 kDa type IV 
collagenase)
collagen catabolism; collagenase activity; extracellular matrix; 





cytoplasm; glucose metabolism; glyceraldehyde-3-phosphate 




inducible double stranded 
RNA dependent inhibitor, 
repressor of (P58 
repressor)
DNA binding; negative regulation of cell proliferation; protein 
binding; regulation of translation; response to stress; signal 
transduction
Hs.177574 5612
SRP14 signal recognition particle 
14 kDa (homologous Alu 
RNA binding protein)
7S RNA binding; cotranslational membrane targeting; protein 
targeting; signal recognition particle
Hs.180394 6727
MALT1 mucosa associated 
lymphoid tissue lymphoma 
translocation gene 1
activation of NF-kappaB-inducing kinase; anti-apoptosis; caspase 
activity; defense response; intracellular; peptidase activity; protein 
binding; proteolysis and peptidolysis; signal transduction
Hs.180566 10892
PSMA7 proteasome (prosome, 
macropain) subunit, alpha 
type, 7
endopeptidase activity; proteasome core complex (sensu Eukarya); 
ubiquitin-dependent protein catabolism
Hs.233952 5688
PSMA3 * proteasome (prosome, 
macropain) subunit, alpha 
type, 7
endopeptidase activity; proteasome core complex (sensu Eukarya); 
ubiquitin-dependent protein catabolism
Hs.346918 5684
LYZ lysozyme (renal 
amyloidosis)
carbohydrate metabolism; cell wall catabolism; cytolysis; defense 
response to bacteria; extracellular space; hydrolase activity, acting 
on glycosyl bonds; inflammatory response; lysozyme activity
Hs.234734 4069
MAFG v-maf musculoaponeurotic 
fibrosarcoma oncogene 
homolog G (avian)
chromatin; nucleus; regulation of transcription, DNA-dependent; 
transcription factor activity; transcription from Pol II promoter
Hs.252229 4097
NRBP nuclear receptor binding 
protein
ATP binding; SH3/SH2 adaptor protein activity; nucleus; protein 
amino acid phosphorylation; protein kinase activity; receptor 
activity; signal transduction; transferase activity
Hs.272736 29959
SCAND1 SCAN domain containing 1 RNA binding; nucleus; protein self binding; regulation of cell cycle; 
regulation of cell proliferation; regulation of transcription, DNA-
dependent; transcription factor activity; transcription factor binding
Hs.274411 51282
EEF1D eukaryotic translation 
elongation factor 1 delta 
(guanine nucleotide 
exchange protein)
eukaryotic translation elongation factor 1 complex; guanyl-
nucleotide exchange factor activity; protein biosynthesis; translation 
elongation factor activity; translational elongation
Hs.334798 1936
NQO1 NAD(P)H dehydrogenase, 
quinone 1
NAD(P)H dehydrogenase (quinone) activity; cytochrome-b5 
reductase activity; cytoplasm; electron transport; nitric oxide 
biosynthesis; oxidoreductase activity; response to toxin; synaptic 
transmission, cholinergic; xenobiotic metabolism
Hs.406515 1728
FABP5 fatty acid binding protein 5 
(psoriasis-associated)
cytoplasm; epidermal differentiation; fatty acid binding; lipid 
metabolism; transport; transporter activity
Hs.408061 2171
S100A11 S100 calcium binding 
protein A11 (calgizzarin)
calcium ion binding; cytoplasm; negative regulation of DNA 
replication; negative regulation of cell proliferation; nucleus
Hs.417004 6282
DIS155E NRAS-related gene DNA binding; RNA binding; male gonad development; regulation of 
transcription, DNA-dependent
Hs.69855 7812
TAL1 T-cell acute lymphocytic 
leukemia 1
DNA binding; cell differentiation; cell proliferation; regulation of 
transcription, DNA-dependent
Hs.73828 6886Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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PTPRN2 protein tyrosine 
phosphatase, receptor 
type, N polypeptide 2
hydrolase activity; integral to plasma membrane; protein amino acid 
dephosphorylation; protein-tyrosine-phosphatase activity; receptor 
activity; transmembrane receptor protein tyrosine phosphatase 
activity
Hs.74624 5799
FKBP4 FK506 binding protein 4, 
59 kDa
FK506 binding; Hsp70/Hsp90 organizing protein activity; 
biological_process unknown; cytoplasm; isomerase activity; nucleus; 
peptidyl-prolyl cis-trans isomerase activity; protein folding
Hs.848 2288
LIPA lipase A, lysosomal acid, 
cholesterol esterase 
(Wolman disease)
N-linked glycosylation; hydrolase activity; lipid catabolism; 
lipoprotein lipase activity; lysosome; sterol esterase activity
Hs.85226 3988
ATF5 activating transcription 
factor 5
DNA binding; RNA polymerase II transcription factor activity; 
nucleus; regulation of cell cycle; regulation of transcription from Pol 
II promoter; transcription corepressor activity
Hs.9754 22809
CD63* lysosomal membrane 
glycoprotein
CD63 serves as an adaptor protein that links its interaction partners 
to the endocytic machinery of the cell/trafficking role
Hs.445570 29186
LAMR1 laminin receptor 1 
(ribosomal protein SA, 67 
kDa)
cell adhesion; cell surface receptor linked signal transduction; 
cytosolic small ribosomal subunit (sensu Eukarya); integrin complex; 
intracellular; laminin receptor activity; protein biosynthesis; 
regulation of translation; structural constituent of ribosome
Hs.181357 3921
2) Catalytic activity/hydrolase activity
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
MMP9 matrix metalloproteinase 9 
(gelatinase B, 92 kDa 
gelatinase, 92 kDa type IV 
collagenase)
(See description above) Hs.151738 4318
GAPD glyceraldehyde-3-
phosphate dehydrogenase
(See description above) Hs.169476 2597
MALT1 mucosa associated 
lymphoid tissue lymphoma 
translocation gene 1
(See description above) Hs.180566 10892
PSMA7 proteasome (prosome, 
macropain) subunit, alpha 
type, 7
(See description above) Hs.233952 5688
PSMA3 * proteasome (prosome, 
macropain) subunit, alpha 
type, 7
(See description above) Hs.346918 5684
LYZ lysozyme (renal 
amyloidosis)
(See description above) Hs.234734 4069
NRBP nuclear receptor binding 
protein
(See description above) Hs.272736 29959
FLJ12671 hypothetical protein 
FLJ12671
exonuclease activity; hydrolase activity; nucleus Hs.301904 81875
NQO1 NAD(P)H dehydrogenase, 
quinone 1
(See description above) Hs.406515 1728
PTPRN2 protein tyrosine 
phosphatase, receptor 
type, N polypeptide 2
(See description above) Hs.74624 5799
FKBP4 FK506 binding protein 4, 
59 kDa
(See description above) Hs.848 2288
LIPA lipase A, lysosomal acid, 
cholesterol esterase 
(Wolman disease)
(See description above) Hs.85226 3988
3) Cell proliferation
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
PRKRIR protein-kinase, interferon-
inducible double stranded 
RNA dependent inhibitor, 
repressor of (P58 
repressor)
(See description above) Hs.177574 5612
SCAND1 SCAN domain containing 1 (See description above) Hs.274411 51282
H41 hypothetical protein H41 cell proliferation; cellular_component unknown; molecular_function 
unknown
Hs.283690 55573
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S100A11 S100 calcium binding 
protein A11 (calgizzarin)
(See description above) Hs.417004 6282
CD164 CD164 antigen, sialomucin cell adhesion; development; endosome; hemopoiesis; immune 
response; integral to plasma membrane; membrane fraction; 
negative regulation of cell adhesion; negative regulation of cell 
proliferation; signal transduction; soluble fraction
Hs.43910 8763
TAL1 T-cell acute lymphocytic 
leukemia 1
(See description above) Hs.73828 6886
ATF5 activating transcription 
factor 5
(See description above) Hs.9754 22809
IL-6 Interleukin 6 reactants also involved in the regulation of immune response, 
hematopoiesis, platelet production, acute phase reaction and bone 
resorption (susceptibility factor for osteopenia), playing a role in the 
aggressiveness of non hodgkin lymphoma by stimulating MMP2 and 
MMP9
Hs.512234 3569
4) Cell growth and maintanance
SCA7 spinocerebellar ataxia 7 
(olivopontocerebellar 
atrophy with retinal 
degeneration)
molecular_function unknown; nuclear organization and biogenesis; 
nucleus; visual perception
Hs.108447 6314
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
TIP47 mannose-6-phosphate 
receptor binding protein 1




inducible double stranded 
RNA dependent inhibitor, 
repressor of (P58 
repressor)
(See description above) Hs.177574 5612
SRP14 signal recognition particle 
14 kDa (homologous Alu 
RNA binding protein)
(See description above) Hs.180394 6727
TUBB5 tubulin beta MGC4083 GTP binding; microtubule; microtubule-based movement; structural 
molecule activity
Hs.274398 84617
SCAND1 SCAN domain containing 1 (See description above) Hs.274411 51282
H41 hypothetical protein H41 (See description above) Hs.283690 55573
FABP5 fatty acid binding protein 5 
(psoriasis-associated)
(See description above) Hs.408061 2171
S100A11 S100 calcium binding 
protein A11 (calgizzarin)
(See description above) Hs.417004 6282
CD164 CD164 antigen, sialomucin (See description above) Hs.43910 8763
CCL1 chemokine (C-C motif) 
ligand 1
calcium ion homeostasis; cell-cell signaling; chemokine activity; 
chemotaxis; extracellular space; immune response; inflammatory 
response; signal transduction; viral life cycle
Hs.72918 6346
TAL1 T-cell acute lymphocytic 
leukemia 1
(See description above) Hs.73828 6886
ATF5 activating transcription 
factor 5
(See description above) Hs.9754 22809
5) Cell cycle
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
SCAND1 SCAN domain containing 1 (See description above) Hs.274411 51282
S100A11 S100 calcium binding 
protein A11 (calgizzarin)
(See description above) Hs.417004 6282
ATF5 activating transcription 
factor 5
(See description above) Hs.9754 22809
6) Regulation of transcription
MAFG v-maf musculoaponeurotic 
fibrosarcoma oncogene 
homolog G (avian)
chromatin; nucleus; regulation of transcription, DNA-dependent; 
transcription factor activity; transcription from Pol II promoter
Hs.252229 4097
SCAND1 SCAN domain containing 1 (See description above) Hs.274411 51282
D1S155E NRAS-related gene (See description above) Hs.69855 7812
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TAL1 T-cell acute lymphocytic 
leukemia 1
(See description above) Hs.73828 6886
ATF5 activating transcription 
factor 5
(See description above) Hs.9754 22809
7) Nucleotide binding
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
KIFC3 kinesin family member C3 ATP binding; microtubule associated complex; motor activity Hs.23131 3801
NRBP nuclear receptor binding 
protein
(See description above) Hs.272736 29959
TUBB-5 tubulin beta MGC4083 (See description above) Hs.274398 84617
8)Nucleobase nucleoside and nucleic acid metabolism
MAFG v-maf musculoaponeurotic 
fibrosarcoma oncogene 
homolog G (avian)
(See description above) Hs.252229 4097
SCAND1 SCAN domain containing 1 (See description above) Hs.274411 51282
S100A11 S100 calcium binding 
protein A11 (calgizzarin)
(See description above) Hs.417004 6282
D1S155E NRAS-related gene (See description above) Hs.69855 7812
TAL-1 T-cell acute lymphocytic 
leukemia 1
(See description above) Hs.73828 6886
ATF-5 activating transcription 
factor 5
(See description above) Hs.9754 22809
9) Signal transducer activity
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
TIP47 mannose-6-phosphate 
receptor binding protein 1
Golgi apparatus; endosome; receptor activity; vesicle-mediated 
transport
Hs.140452 10226
NRBP nuclear receptor binding 
protein
(See description above) Hs.272736 29959
CCR1 chemokine (C-C motif) 
receptor 1
C-C chemokine receptor activity; G-protein signaling, coupled to 
cyclic nucleotide second messenger; cell adhesion; cell-cell signaling; 
chemotaxis; cytosolic calcium ion concentration elevation; immune 
response; inflammatory response; integral to plasma membrane; 
rhodopsin-like receptor activity
Hs.301921 1230
CCL1 chemokine (C-C motif) 
ligand 1
calcium ion homeostasis; cell-cell signaling; chemokine activity; 
chemotaxis; extracellular space; immune response; inflammatory 
response; signal transduction; viral life cycle
Hs.72918 6346
PTPRN2 protein tyrosine 
phosphatase, receptor 
type, N polypeptide 2
hydrolase activity; integral to plasma membrane; protein amino acid 
dephosphorylation; protein-tyrosine-phosphatase activity; receptor 
activity; transmembrane receptor protein tyrosine phosphatase 
activity
Hs.74624 5799
10) Immune response/ defence
CD2BP2 CD2 antigen (cytoplasmic 
tail) binding protein 2
antimicrobial humoral response (sensu Vertebrata); cytoplasm Hs.202677 10421
LYZ lysozyme (renal 
amyloidosis)
(See description above) Hs.234734 4069
CCR1 chemokine (C-C motif) 
receptor 1
(See description above) Hs.301921 1230
CD164 CD164 antigen, sialomucin (See description above) Hs.43910 8763
CCL1 chemokine (C-C motif) 
ligand 1
(See description above) Hs.72918 6346
MALT1 mucosa associated 
lymphoid tissue lymphoma 
translocation gene 1
activation of NF-kappaB-inducing kinase; anti-apoptosis; caspase 
activity; defense response; intracellular; peptidase activity; protein 
binding; proteolysis and peptidolysis; signal transduction
Hs.180566 10892
NKG7* Natural killer cell group 7 
sequence
Expressed in activated T cells, alpha LAK cells in kidney, liver, lung 
and pancreas. Not expressed in brain, heart, or skeletal muscle. 
Expressed at high levels in TCR gamma delta-expressing CTL 
clones, and in some TCR alpha beta-expressing CTL clones (both 
CD4+ and CD8+), but is not expressed in other TCR alpha beta-
expressing CTL clones and in cell lines representing Bcells, 
monocytes, and myeloid cells
Hs.10306 4818
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NKTR* NK cell tumor recognition 
protein
Activation of NK cell eleveted levels upon recognition of tumors by 
NK
Hs.432885 4820
MPEG1* likely ortholog of mouse 
macrophage expressed 
gene 1
Mpg-1 is a novel gene that may share a distant ancestry to perforin, 
a lytic protein found in cytotoxic T lymphocytes and natural killer 
cells
Hs.549280 219972
CCL3L1* chemokine (C-C motif) 
ligand 3-like 1
chemokine activity; chemotaxis; extracellular; immune response; 
inflammatory response; negative regulation of cell proliferation
Hs.387650 6349
IL-6 Interleukin 6 (See description above) Hs.512234 3569
11) Cell adhesion
CCR1 chemokine (C-C motif) 
receptor 1
(See description above) Hs.301921 1230
CD164 CD164 antigen, sialomucin (See description above) Hs.43910 8763
FKBP4 uncharacterized 
hematopoietic stem/
progenitor cells protein 
MDS028
cell-matrix adhesion; integrin complex Hs.848 55846
LAMR1* laminin receptor 1 
(ribosomal protein SA, 67 
kDa)
(See description above) Hs.181357 3921
ICAM3* intracellular adhesion 
molecule 3




ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
FABP5 fatty acid binding protein 5 
(psoriasis-associated)
cytoplasm; epidermal differentiation; fatty acid binding; lipid 
metabolism; transport; transporter activity
Hs.408061 2171




epidermal differentiation; intermediate filament; structural 
constituent of cytoskeleton
Hs.433845 3852
CD164 CD164 antigen, sialomucin (See description above) Hs.43910 8763
D1F155E NRAS-related gene (See description above) Hs.69855 7812
TAL1 T-cell acute lymphocytic 
leukemia 1
(See description above) Hs.73828 6886
13) Biosynthesis regulation of translation
PRKRIR protein-kinase, interferon-
inducible double stranded 
RNA dependent inhibitor, 
repressor of (P58 
repressor)
(See description above) Hs.177574 5612
EEF1D eukaryotic translation 
elongation factor 1 delta 
(guanine nucleotide 
exchange protein)
(See description above) Hs.334798 1936
NQO1 NAD(P)H dehydrogenase, 
quinone 1
(See description above) Hs.406515 1728
LIPA lipase A, lysosomal acid, 
cholesterol esterase 
(Wolman disease)
N-linked glycosylation; hydrolase activity; lipid catabolism; 
lipoprotein lipase activity; lysosome; sterol esterase activity
Hs.85226 3988
LAMR1 laminin receptor 1 
(ribosomal protein SA, 67 
kDa)
(See description above) Hs.181357 3921
EEF2* eukaryotic translation 
elongation factor 2
translational elongation, GTP binding translation elongation factor 
activity, protein biosynthesis
Hs.75309 1938
EIF5A* eukaryotic translation 
initiation factor 5A
regulation of translational initiation, nucleic acid binding, translation 




KFC3 kinesin family member C3 ATP binding; microtubule associated complex; motor activity Hs.23131 3801
TUBB-5 tubulin beta MGC4083 (See description above) Hs.274398 84617




epidermal differentiation; intermediate filament; structural 
constituent of cytoskeleton
Hs.433845 3852
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of translation; 14) Cytoskeleton 15) Transport 16) Cell
death (Table 2, also refer to this table for details on gene
name abbreviations and single gene function).
Signature IFNs upregulated all the genes classified in 7 out
of 16 categories: 5) Cell cycle, 6) Regulation of transcrip-
tion, 7) Nuclear binding, 8) Nucleobase/ nucleoside and
nucleic acid metabolism, 9 Signal transducer activity
(except for one gene), 14) Cytoskeleton, and 15) Trans-
port. These results indicate that not only are signature
IFNs capable of affecting simultaneously a variety of vital
cellular functions in MPs but these IFNs are powerful
inducer of gene transcription and key regulators of cellular
responses to diverse types of stimuli.
Both the signature and non-signature IFNs upregulated
MP genes in 7 categories 1) Metabolism/protein metabo-
lism; 2) Catalytic activity/hydrolase activity 3) Cell prolif-
eration, 4) Cell growth and maintenance 10) Immune
response/defense, 11) Cell adhesion, and 13) Biosynthe-
sis/regulation of translation. Twenty four genes were clas-
sified into the 1) Metabolism/protein metabolism, the
functional category that contained the greatest number of
genes. The large majority of metabolic genes belonged to
vital pathways of cell survival. Activation of metabolic
genes by the signature and non-signature IFNs affected
distinct and yet equally important groups of genes.
Seventeen metabolic genes were upregulated by signature-
IFNs and these 17 genes affected major metabolic path-
ways such as MAP/ERK/MAPKK pathway (ZAK), glycoly-
sis/glucose metabolism (GAPD), NADPH
dehydrogenase/ oxidoreductase activity (NQO1), ubiqui-
tin dependent protein catabolism/ proteasome
endopeptidase activity (PSMA7, PSMA3), lipid metabo-
lism (FABP5), endocytic machinery of cell trafficking
(CD63) and nuclear DNA binding related to cell differen-
tiation and proliferation (TAL1, DIS155E). Seven out of
24 metabolic genes were upregulated by non-signature-
IFNs and were primarily related to enzymatic activities in
protein biosynthesis (LAMR1), proteolysis and peptidoly-
sis (MALT1), lipid catabolism(LIPA) and cytolysis (LYZ).
The functional categories 10) Immune genes and 11) Cell
adhesion are of particular significance because they may
be the basis of the selective immune-polarization of MPs
induced by the different IFNs. In particular, immune
genes such, IL-6, chemokine receptor 1 (CCR1), chemok-
ine ligand 1 (CCL1) [50], CD2BP2 and chemokine ligand
3-like 1 (CCL3L1), were specifically expressed by the sig-
nature IFNs. CCR1 encodes a member of the beta chem-
okine receptor family, that binds macrophage
inflammatory protein 1 alpha (MIP-1 alpha), regulated
on activation normal T expressed and secreted protein
(RANTES), monocyte chemoattractant protein 3 (MCP-
3), and myeloid progenitor inhibitory factor-1 (MPIF-1).
CCRI is a critical receptor for the recruitment of effector
15)Transport
TIP47 mannose-6-phosphate 
receptor binding protein 1
(See description above) Hs.140452 10226
SRP14 signal recognition particle 
14 kDa (homologous Alu 
RNA binding protein)
(See description above) Hs.180394 6727
TUBB-5 tubulin beta MGC4083 (See description above) Hs.274398 84617
FABP5 fatty acid binding protein 5 
(psoriasis-associated)
(See description above) Hs.408061 2171
16) Cell Death
ZAK sterile alpha motif and 
leucine zipper containing 
kinase AZK
(See description above) Hs.115175 51776
MALT1 mucosa associated 
lymphoid tissue lymphoma 
translocation gene 1
(See description above) Hs.180566 10892
LYZ lysozyme (renal 
amyloidosis)
(See description above) Hs.234734 4069
Genes in blue rectangles are up-regulated in MP stimulated by "signature IFNs" (and down-regulated in non-signature interferons). Genes in orange 
rectangles are up-regulated in MP stimulated by non-signature IFN (and downregulated in signature interferons). Genes belonging to more than one 
functional group may represent central and shared switches in pathways directly influenced by IFNs' activity. Genes in torqoise characters did not 
classify in any of the categories mined by DAVID software (PSMA3, NKTR, NKG7, CD63, EEF2) and were manually entered in the appropriate 
group on the basis of Entrez cross database annotation and Genecard http://www.ncbi.nlm.nih.gov/Entrez; http://bioinfo.weizmann.ac.il/cards/
index.shtml
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immune cells to the site of inflammation [10, 51, 52 Cell
Migration Consortium http://wrpx00.bioch.virginia.edu/
cellmig_test/cmcweb/resource/cmckb/
sci_molecules_list.html] CCL3L1 binds to several chem-
okine receptors including chemokine binding protein 2
and chemokine (C-C motif) receptor 5 (CCR5). CCR5 is a
co-receptor for HIV, and binding of CCL3L1 to CCR5
inhibits HIV entry [52,53]. Thus regulation of CCL3L1 by
signature-IFNs may represent a selective mechanism of
viral immunity.
The activation of transcription of CCL1 and CD2BP2 in
MPs by signature IFNs is an interesting finding consider-
ing that these two genes are normally activated in T cells.
CCL1/ inflammatory cytokine I-309 is normally released
by activated T cells during inflammation [52], and the
CD2BP2 adaptor binds the CD2 cytoplasmic tail and reg-
ulates interleukin-2 production [54]. The modulation of
CCL3L1, CCR1, CCL1, CD2BP2 by the signature-IFNs
confirms the dominant role of these factors in the first
phase of the innate immune response, inflammation,
viral defense, and regulation of inflammatory cytokines
such as IL-2.
Macrophage expressed gene 1 (MPEG1) [55,56] (NKG7)
[57], NKTR [58], MALT-1, LYZ AND CD164 were upregu-
lated by the non-signature group suggesting that these
genes with potential cytotoxic and inflammatory func-
tions may increase the effector function of MPs. It is
important to notice that IFN-αWA and IFN-αK behaved as
the non-signature IFNs regarding activation of immune
genes (NKTR, CD164 and MPEG) and thus did not cluster
with the signature IFNs (Figure 4). These two IFN alphas
may contribute to a special type of MP polarization which
may be leading to an intermediate phase of activation in
between alternative and classical pathways. The non-sig-
nature IFNs also induced the expression of genes involved
with cell adhesion and complement regulation: LAMR1
[59], ICAM3 [60], CD164 [61] and complement compo-
nent 1 receptor subcomponent (C1R) [62] providing fur-
ther evidence that IFNs belonging to the non-signature-
like group may polarize MPs towards the classical path-
way of monocyte activation.
Signature IFNs specifically affected a group of genes
involved in eukaryotic translation and listed in category
13) biosynthesis/regulation of translation: eukaryotic
translation initiation factor 5A (EIF5A) [63], eukaryotic
translation elongation factor 1 delta (EEF1D) [64], and
eukaryotic translation elongation factor 2 (EEF2) [65].
This supports the notion that the powerful stimulus of
activation induced by the signature IFNs on immune cells
is a global type of regulation directly affecting target mol-
ecules at the levels of both transcription and translation.
Genes upregulated by signature IFNs and belonging to
more than one functional group were particularly interest-
ing because they could represent central and shared
molecular and cellular switches in pathways not previ-
ously reported to be influenced by the signature-IFNs'
activity. The ZAK (sterile alpha motif and leucine zipper
containing kinase AZK) gene appeared to be a very domi-
nant signature IFNs gene since it was shared by 9 out of 16
functional groups analyzed. ZAK encodes a mixed lineage
kinase with a leucine zipper and a sterile alpha motif. The
expression of ZAK in mammalian cells may lead to the
activation of the JNK/SAPK (MAP kinase family) pathway
as well as the activation of the transcription factor, NF-
kappaB. Furthermore over-expression of ZAK leads to
apoptosis in tumor cell lines [66].
Phylogenic analysis
To determine whether a correlation existed between close-
ness of the primary amino acid sequence of type I IFNs
and functional similarities we compared the sequence
relationship among the 13 αIFNs and IFN-β. The phylo-
genic analysis did not predict the differentiation between
signature and non-signature IFNs and, in fact, the signa-
ture IFNs included proteins phylogenically quite unre-
lated  (IFN-αWA, IFN-αF and IFN-αB2 Figure 5).
Therefore, more limited domains of the structure of each
IFN may be responsible for their different functional
properties. Comparison of the primary amino acid
sequences of IFN-β and the 13 αIFNs identified several
similarities (Figure 6). Although there was no exclusive
sequence variation that could distinguish signature from
non-signature IFNs, some amino acids were more likely
present in one or the other group. Three regions appeared
to be most significant in distinguishing the subgroups of
the protein and included: residues 93 through 109, resi-
dues 174 through 188-9, and at residue 123. The differ-
ences were greatest at residues 123 and 179 where
signature IFNs (except IFN-β) had the same amino acid (I
at 124 and T at 179, red arrows, figure 6), but these amino
acids were present in only 2 of 6 non-signature αIFNs.
Discussion
Interferons are important cytokines with antiviral, anti-
proliferative, and immune modulatory functions [67].
The IFNs are divided into two classes, type I and type II.
The type I IFNs include the α, β, τ and ωIFNs, while IFN-γ
is the only type II IFN. It has generally been believed that
the various type I IFNs have markedly different biological
functions and the immune modulatory effects of type I
IFNs vary widely among individual IFNs. IFNs exert many
of their effects by modulating MP functions [1,68]. The
stimulation of MPs by cytokines, including IFNs, results in
the activation of several different pathways; some of
which are common to different stimuli and some that are
unique for each stimuli. This study shows that most typeJournal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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I IFNs share some MP activation pathways and functional
differences among IFNs are due to additional diversifica-
tion of their function through other pathways of activa-
tion. In particular, the effects of seven IFN-α and IFN-β on
LPS-stimulated MPs were remarkably similar. These simi-
larities were not apparent after 4 hours of stimulation and
required a longer process of down-stream activation that
could be identified in our study at 9 hours.
Since we only studied one subject, the transcriptional pro-
file presented in this study may not represent the plethora
of biological effects that IFN can induce under in vitro or in
vivo conditions because secondary autocrine (in different
donors) and paracrine modulation through the cytokine
network following a primary stimulation may introduce
diverse on and off switches that could override the origi-
nal signal. Nevertheless, this is an informative analysis on
the effects of IFN subtypes on the late stages of LPS stimu-
lation and, therefore, maybe most informative on the way
mononuclear phagocytes are polarized by IFNs during
their activation and or maturation.
A group of 42 signature genes was upregulated by all the
tested IFNs. Furthermore, all 42 signature genes have
previously been found to be associated with IFNs (Table
1). The analysis of a group of 83 genes that were differen-
tially expressed among the signature and non-signature
IFNs found that the signature IFNs affected a variety of cell
functions not only by being potent inducers of gene tran-
scription and translation but by directly and indirectly
affecting crucial regulatory cell cycle and metabolic path-
ways. In addition, signature IFNs were found to be partic-
ularly involved in the first phase of the innate immune
response, inflammation, and viral defense. In contrast,
the non-signature IFNs gene profiling suggested that these
immune-modulators can trigger cytotoxic responses and
likely increase the effector functions of MPs or classical
pathways of monocyte activation.
Type I IFNs play an important role in autoimmune disor-
ders. Serum levels of IFN-α are increased in some patients
with the autoimmune SLE. The gene expression profiles of
peripheral blood MPs is also abnormal in patients with
SLE. Analysis of peripheral blood MPs from patients with
SLE has found that IFN-inducible genes are upregulated in
almost all patients with SLE [2,3,67] and the genes upreg-
ulated in SLE patients were similar to those upregulated in
peripheral blood MPs stimulated in vitro with IFN-α [1-
3,67]. As a result the IFN-inducible genes that are
upregulated in SLE have been called IFN signature genes.
Many of the IFN-inducible genes up regulated in SLE
patients are the same genes we found were upregulated by
the treatment of LPS-stimulated MPs with the eight signa-
ture IFNs. The genes upregulated both in MPs from
patients with SLE and by LPS-stimulated genes treated
with the signature IFNs included OAS1, OAS2, LY6E,
MX1, CIG5, and hepatitis C-associated microtubular
aggregation protein (44 kD) [2,3,67].
Hilkens et al studied the effects of three IFNs, the signature
IFNs, IFN-α1, IFN-α2, and the non-signature IFN, IFN-αF
on the expression of 150 IFN stimulated genes by den-
dritic cells derived from peripheral blood mononuclear
cells and found that the qualitative effects of the three
Phylogenic comparison of IFNs Figure 5
Phylogenic comparison of IFNs. A multiple alignment cluster of the amino acid sequences of the 13 αIFNs, βIFN, and γIFN 
was preformed with Cluster W. The signature IFNs are shown in blue and the non-signature IFNs are shown in red.Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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IFNs were similar but there were quantitative differences
[69]. The IFN stimulated genes were more highly induced
by IFN-α2 and IFN-αF than IFN-α1, but these differences
were overcome by increasing the concentration of IFN-αI.
There was, however, one exception. The expression of IP-
10 was induced by IFN-α2 and IFN-αF, but not by IFN-αI.
This supports our finding that the differences in transcrip-
tional profiles of MPs treated by different type I IFNs are
due to distinct effects of each of the IFNs rather than dif-
ferences in the activation of IFN-specific genes.
Although increased serum levels of IFN-α and IFN-ω have
been found in some patients with SLE [67], the
proportion of patients with detectable IFN in serum is
much smaller than the proportion of SLE patients with
peripheral blood MPs that display evidence of IFN-stimu-
lation by gene expression profiling [1]. However, since the
IFN genes upregulated in MPs from SLE patients were sim-
ilar to those upregulated by MPs stimulated with IFN-α,
most studies have measured IFN-α serum levels in
patients with SLE. Our study suggests other type I IFNs in
addition to IFN-α could be responsible of the abnormal
MP gene expression profiles in patients with SLE. It may
be that IFNs other than IFN-α are increased in SLE patients
but the ELISA assays used to measure IFN-α may not
detect other type I IFNs that could result in a similar MP
gene expression profile. One commonly used IFN-α ELISA
kit recognizes IFN-αA, IFN-α2, IFN-αA/D, IFN-αD, IFN-
Comparison of the amino acid sequences of IFN-β and the 13 α-IFNs studied Figure 6
Comparison of the amino acid sequences of IFN-β and the 13 α-IFNs studied. The signature IFNs are shown in blue 
and the non-signature IFNs are shown in red. Amino acids that were more likely to be present in signature IFNs are shown in 
gray and those more likely to be present in non-signature IFNs are shown in torqoise. Amino acids present in IFN-β, y and all 
13 αIFNs are shown in yellow.Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
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αK, and IFN-α4b, but not IFN-β or IFN-γ (BioSource Inter-
national USA, Inc., Camarillo, CA) another kit recognizes
IFN-αA, α2, αA/D, αB2, αC, αD, αG, αH, αI, αJ, αK, αWA,
and α4b (PBL laboratories multi species IFN α elisa kit).
Type I IFNs belong to a family of homologous helical
cytokines. The various αIFNs have approximately 80%
amino acid sequence homology and the α and βIFNs have
approximately 30% sequence homology [70]. The α and
βIFNs, however, all have a similar three-dimensional
structure. They are made up of nearly parallel bundles of
five α helices. In addition to the shared tertiary structure,
the α and βIFNs signal cells through the same receptor
complex, the common IFN-α/β receptor (IFNAR). This
receptor is made up of two subunits IFNAR1 and IFNAR2.
IFNAR2 plays a greater role in binding type I IFNs than
IFNAR1. Although IFNAR2 is the major IFN binding
component of the receptor, the formation of the tertiary
complex of IFNAR2 and IFN with IFNAR1 increases the
affinity of IFN to IFNAR2 up to 20-fold.
The binding of IFN-α2 to IFNAR1 and IFNAR2 has been
extensively investigated [64-68]. IFNAR2 binds to the A
helix of IFN-α2 (residues 12–15), the AB loop (residues
26–35), and the E helix (residues 144–153) [71]. The
opposite face of IFN-α2, the B and C helices, is involved
with interactions with IFNAR1 [70]. Modeling of the
interactions of IFNAR2 and IFN-α2 based on multidimen-
sional NMR analysis of these molecules found that IFN-
α2 residues R33, D35 and R149 interact with a
hydrophilic strip of matching charges in IFNAR2. Other
important IFN-α2 residues involved with the binding to
IFNAR2 are M16 and A19 of the A helix, L26 and L30 of
the AB loop, and A145 and M148 of the E helix. Mutagen-
esis analysis of IFN-α2 found six residues important in
IFNAR2 binding: L30, R33, R144, A145, and M148. The
residues we found that differ between the signature and
non-signature IFNs are in areas that are not critical to the
binding of IFN-α2 to IFNAR2. Our findings suggest that
changes in IFN-α2 residues in the carboxy end (residues
174, 177, 178-9, 183 and 189), the D helix (residue 124)
and the C helix (residues 94, 101, 102, 103, 106, and 109)
may affect the function of α and βIFNs and are be respon-
sible for the functional similarities among the signature
IFNs. We speculate that these changes may affect the terti-
ary structure of type I IFNs and there binding by IFNAR1.
Conclusion
MPs demonstrate a biphasic response to cytokine stimula-
tion and 9 hours after IFN treatment LPS-stimulated MPs
had a striking gene expression profile. When treated with
eight type I IFNs the same group of genes were strongly
upregulated. IFNs play a critical role in host defense and
the redundant function of these signature IFNs may help
insure that there are multiple pathways of activation of
potent host antiviral and antitumor responses. Since sev-
eral different IFNs have similar effects, when clinical or
molecular evidence suggest that serum IFN levels are
increased, assays that detect a wide range of type I IFNs
should be used to measure soluble IFN levels.
List of Abbreviations
Mp = mononuclear macrophage
PBMC = peripheral blood mononuclear cells
IFN = interferon
CM = Complete medium
OM = OPTI-MEM
LPS = lipopolysaccharide
TNF = tumor necrosis factor
References
1. Banchereau J, Pascual V, Palucka AK: Autoimmunity through
cytokine-induced dendritic cell activation.  Immunity 2004,
20(5):539-50. Review.
2. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J,
Pascual V: Interferon and granulopoiesis signatures in sys-
temic lupus erythematosus blood.  J Exp Med 197(6):711-23.
2003 Mar 17
3. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA,
Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK,
Behrens TW: Interferon-inducible gene expression signature
in peripheral blood cells of patients with severe lupus.  Proc
Natl Acad Sci U S A 2003, 100:2610-5.
4. Nagorsen D, Deola S, Smith K, Wang E, Monsurro V, Zanovello P,
Marincola FM, Panelli MC: Polarized monocyte response to
cytokine stimulation.  Genome Biology 2005, 6:R15.
5. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage
polarization: tumor-associated macrophage as a paradigm
for polarized M2 mononuclear phagocytes.  Trends Immunol
2002, 23:549-555.
6. Takeda K, Kaisho T, Akira S: Toll-like receptors.  Annu Rev Immunol
2003, 21:335-376.
7. Anderson KV: Toll signaling pathways in the innate immune
response.  Curr Opin Immunol 2000, 12:13-19.
8. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM: The
dual role of IL-10.  Trends Immunol 2002, 24:36-43.
9. Gordon S: Alternative activation of macrophages.  Nature
Reviews 2003, 3:23-35.
10. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M:
Thechemokine system in diverse forms of macrophage acti-
vation and polarization.  Trends Immunol 2004, 25:677-86.
11. Huang Q, Liu D, Majewski P, et al.: The plasticity of dendritic cell-
responses to pathogens and their components.  Science 2001,
294:870-875.
12. Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity
mRNA amplification for gene profiling using cDNA
microarrays.  Nature Biotech 2000, 17:457-459.
13. Wang E, Marincola FM: Amplification of small quantities of
mRNA for transcript analysis. In: Bowtell D, Sambrook J,
eds. DNA arrays – A Molecular Cloning Manual.  Cold Springs
Harbor, NY: Cold Spring Harbor Laboratory Press; 2002:204-213. 
14. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis
and display of genome-wide expression patterns.  Proc Natl
Acad Sci U S A 1998, 95:14863-14868.
15. Ross DT, Scherf U, Eisen MB, et al.: Systematic variation in gene
expression patterns in human cancer cell lines.  Nature Genetics
2000, 24:227-235.Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
Page 20 of 21
(page number not for citation purposes)
16. Regad T, Chelbi-Alix MK: Role and fate of PML nuclear bodies
in response to interferon and viral infections.  Oncogene 2001,
20:7274-86.
17. Espert L, Rey C, Gonzalez L, Degols G, Chelbi-Alix MK, Mechti N,
Gongora C: The exonuclease ISG20 is directly induced by syn-
thetic dsRNA via NF-kappaB and IRF1 activation.  Oncogene
2004, 23:4636-40.
18. Espert L, Degols G, Gongora C, Blondel D, Williams BR, Silverman
RH, Mechti N: ISG20, a new interferon-induced RNase specific
for single-stranded RNA, defines an alternative antiviral
pathway against RNA genomic viruses.  J Biol Chem 2003,
278:16151-8.
19. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K:
Analysis on the association of human BLYS (BAFF,
TNFSF13B) polymorphisms with systemic lupus erythema-
tosus and rheumatoid arthritis.  Genes Immun 2002, 3:424-9.
20. Surin B, Rouillard D, Bauvois B: Interactions between human
monocytes and fibronectin are suppressed by interferons
beta and gamma, but not alpha: correlation with Rho-paxil-
lin signaling.  Int J Mol Med 2002, 10:25-31.
21. Arnheiter H, Meier E: Mx proteins: antiviral proteins by chance
or by necessity?  New Biol 1990, 2:851-7.
22. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A,
Ivashkiv LB: IFN-alpha priming results in a gain of proinflam-
matory function by IL-10: implications for systemic lupus
erythematosus pathogenesis.  J Immunol 2004, 172:6476-81.
23. Taylor MW, Grosse WM, Schaley JE, Sanda C, Wu X, Chien SC, Smith
F, Wu TG, Stephens M, Ferris MW, McClintick JN, Jerome RE, Eden-
berg HJ: Global effect of PEG-IFN-alpha and ribavirin on gene
expression in PBMC in vitro.  J nterferon Cytokine Res 2004,
24:107-18.
24. Samuel CE: Antiviral actions of interferons.  Clin Microbiol Rev
2001, 14:778-809.
25. Zhang J, Das SC, Kotalik C, Pattnaik AK, Zhang L: The latent mem-
brane protein 1 of Epstein-Barr virus establishes an antiviral
state via inductionof interferon-stimulated genes.  J Biol Chem
2004, 279:46335-42.
26. Gongora C, Tissot C, Cerdan C, Mechti N: The interferon-induc-
ible Staf50 gene is downregulated during T cell costimula-
tion by CD2 and CD28.  J Interferon Cytokine Res 2000, 20:955-61.
27. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman
BA, Huibregtse JM, Krug RM: The UbcH8 ubiquitin E2 enzyme is
also the E2 enzyme for ISG15, an IFN-alpha/beta-induced
ubiquitin-like protein.  Proc Natl Acad Sci U S A 2004, 101:7578-82.
28. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY: Analysis of gene
expression profiles in human systemic lupus erythematosus
using oligonucleotide microarray.  Genes Immun 2003, 4:177-86.
29. Brem R, Oraszlan-Szovik K, Foser S, Bohrmann B, Certa U: Inhibi-
tion of proliferation by 1-8U in interferon-alpha-responsive
and non-responsive cell lines.  Cell Mol Life Sci 2003, 60:1235-48.
30. Liu H, Kang H, Liu R, Chen X, Zhao K: Maximal induction of a
subset of interferon target genes requires the chromatin-
remodeling activity of the BAF complex.  Mol Cell Biol 2002,
22:6471-9.
31. Kloetzel PM, Ossendorp F: Proteasome and peptidase function
in MHC-class-I-mediated antigen presentation.  Curr Opin
Immunol 2004, 16:76-81.
32. Hendil KB, Khan S, Tanaka K: Simultaneous binding of PA28 and
PA700activators to 20 S proteasomes.  Biochem J 1998,
332:749-54.
33. Cheng YS, Patterson CE, Staeheli P: Interferon-induced guan-
ylate-binding proteins lack an N(T)KXD consensus motif and
bind GMP in addition to GDP and GTP.  Mol Cell Biol 1991,
11:4717-25.
34. Chin KC, Cresswell P: Viperin (cig5), an IFN-inducible antiviral
protein directly induced by human cytomegalovirus.  Proc Natl
Acad Sci U S A 2001, 98:15125-30. Erratum in: Proc Natl Acad Sci U
S A 2002;99:2460.
35. Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert
JR, Shekhtman EM, Tomei LD, Umansky SR, Kiefer MC: Interferon-
gamma modulates a p53-independent apoptotic pathway
and apoptosis-related gene expression.  J Biol Chem 1997,
272:16351-7.
36. Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and tran-
scriptional activation in response to IFNs and other extracel-
lular signaling proteins.  Science 1994, 264:1415-21.
37. Lucarelli E, Kaplan DR, Thiele CJ: Selective regulation of TrkA
and TrkB receptors by retinoic acid and interferon-gamma
in human neuroblastoma cell lines.  J Biol Chem 1995,
270:24725-31.
38. Kitamura A, Takahashi K, Okajima A, Kitamura N: Induction of the
human gene for p44, a hepatitis-C-associated microtubular
aggregate protein, by interferon-alpha/beta.  Eur J Biochem
1994, 224:877-83.
39. de Veer MJ, Sim H, Whisstock JC, Devenish RJ, Ralph SJ: IFI60/
ISG60/IFIT4, a new member of the human IFI54/IFIT2 family
of interferon-stimulated genes.  Genomics 1998, 54:267-77.
40. Levy D, Larner A, Chaudhuri A, Babiss LE, Darnell JE Jr: Interferon-
stimulated transcription isolation of an inducible gene andi-
dentification of its regulatory region.  Proc Natl Acad Sci U S A
1986, 83:8929-33.
41. Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, McIndoe RA,
Crawford JM, Nelson DR, She JX, Liu C: Gene expression associ-
ated with interferon alfa antiviral activity in an HCV replicon
cell line.  Hepatology 2003, 37:1180-8.
42. Tang JP, Gu YY, Shen N, Ye S, Qian J, Hua J, Chen XG, Chen SL, Bao
CD, Wang Y, Zhang W: Interferon-inducible genes lymphocyte
antigen 6 complex E and tetratricopeptide repeats 1 are cor-
related with clinical features of patients with systemic lupus
erythematosus.  Zhonghua Yi Xue Za Zhi 2004, 84:1157-60. Chinese
43. Le Page C, Genin P, Baines MG, Hiscott J: Interferon activation
and innate immunity.  Rev Immunogenet 2000, 2:374-86.
44. Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ozdemir A,
Yi T, Williams BR, Borden EC: Novel growth and death related
interferon-stimulated genes (ISGs) in melanoma: greater
potency of IFN-beta compared with IFN-alpha2.  J Interferon
Cytokine Res 2003, 23:745-56.
45. Imaizumi T, Hatakeyama M, Yamashita K, Yoshida H, Ishikawa A,
Taima K, Satoh K, Mori F, Wakabayashi K: Interferon-gamma
induces retinoic acid-inducible gene-I in endothelial cells.
Endothelium 2004, 11:169-73.
46. Ritchie KJ, Hahn CS, Kim KI, Yan M, Rosario D, Li L, de la Torre JC,
Zhang DE: Role of ISG15 protease UBP43 (USP18) in innate
immunity to viral infection.  Nat Med 2004, 10:1374-8.
47. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI,
Peterson LF, Shuai K, Zhang DE: Protein ISGylation modulates
the JAK-STAT signaling pathway.  Genes Dev 2003, 17:455-60.
48. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K,
Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S: Interferon-
alpha induction through Toll-like receptors involves a direct
interaction of IRF7 with MyD88 and TRAF6.  Nat Immunol
2004, 5:1061-8.
49. Williams BR: Signal transduction and transcriptional regula-
tion of interferon-alpha-stimulated genes.  J Interferon Res 1991,
11:207-13.
50. Tamguney G, Van Snick J, Fickenscher H: Autocrine stimulation of
rhadinovirus-transformed T cells by the chemokine CCL1/I-
309.  Oncogene 2004, 23:8475-85.
51. Zabel BA, Silverio AM, Butcher EC: Chemokine-like receptor 1
expression and chemerin-directed chemotaxisdistinguish
plasmacytoid from myeloid dendritic cells in human blood.  J
Immunol 2005, 174:244-51.
52. Cell Migration Consortium   [http://wrpx00.bioch.virginia.edu/
cellmigtest/cmcweb/resorcue/cmckb/sci molecule list.html]
53. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G,
Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin
BH, Bradley W, Clark RA, Anderson SA, O'connell RJ, Agan BK,
Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK: The Influence of
CCL3L1 Gene-Containing Segmental Duplications on HIV-
1/AIDS Susceptibility.  Science  in press. 2005 Jan 6
54. Freund C, Kuhne R, Yang H, Park S, Reinherz EL, Wagner G:
Dynamic interaction of CD2 with the GYF and the SH3
domain of compartmentalized effector molecules.  EMBO J
2002, 21:5985-95.
55. Mah SA, Moy GW, Swanson WJ, Vacquier VD: A perforin-like pro-
tein from a marine mollusk.  Biochem Biophys Res Commun 2004,
316:468-75.
56. Spilsbury K, O'Mara MA, Wu WM, Rowe PB, Symonds G, Takayama
Y: Isolation of a novel macrophage-specific gene by differen-
tial cDNA analysis.  Blood 1995, 85:1620-9.
57. Medley QG, Kedersha N, O'Brien S, Tian Q, Schlossman SF, Streuli
M, Anderson P: Characterization of GMP-17, a granule mem-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2005, 3:24 http://www.translational-medicine.com/content/3/1/24
Page 21 of 21
(page number not for citation purposes)
brane protein that moves to the plasma membrane of natu-
ral killer cells following target cell recognition.  Proc Natl Acad
Sci U S A 1996, 93:685-689.
58. Anderson SK, Gallinger S, Roder J, Frey J, Young HA, Ortaldo JR: A
cyclophilin-related protein involved in the function of natural
killer cells.  Proc Natl Acad Sci U S A 1993, 90:542-6.
59. Kim WH, Lee BL, Jun SH, Song SY, Kleinman HK: Expression of 32/
67-kDa laminin receptor in laminin adhesion-selected
human colon cancer cell lines.  Br J Cancer 1998, 77:15-20.
60. Simmons DL: The role of ICAM expression in immunity and
disease.  Cancer Surv 1995, 24:141-55. Review.
61. Zannettino AC, Buhring HJ, Niutta S, Watt SM, Benton MA, Simmons
PJ: The sialomucin CD164 (MGC-24v) is an adhesive glyco-
protein expressed by human hematopoietic progenitors and
bone marrow stromal cells that serves as a potent negative
regulator of hematopoiesis.  Blood 1998, 92:2613-28.
62. Rozanov DV, Sikora S, Godzik A, Postnova TI, Golubkov V, Savinov
A, Tomlinson S, Strongin AY: Non-proteolytic, receptor/ligand
interactionsassociate cellular membrane type-1 matrix met-
alloproteinase with the complement component C1q.  J Biol
Chem 2004, 279:50321-8.
63. Li AL, Li HY, Jin BF, Ye QN, Zhou T, Yu XD, Pan X, Man JH, He K,
Yu M, Hum MR, Wang J, Yang SC, Shen BF, Zhang XM: A novel
eIF5A complex functions as a regulator of p53 and p53-
dependent apoptosis.  J Biol Chem 2004, 279:49251-8.
64. Kawaguchi Y, Kato K, Tanaka M, Kanamori M, Nishiyama Y, Yama-
nashi Y: Conserved protein kinases encoded by herpesviruses
and cellular proteinkinase cdc2 target the same phosphor-
ylation site in eukaryotic elongation factor 1 delta.  J Virol
2003, 77:2359-68.
65. Nilsson A, Carlberg U, Nygard O: Kinetic characterisation of the
enzymatic activity of the eEF-2-specific Ca2(+)-and calmod-
ulin-dependent protein kinase III purified from rabbit
reticulocytes.  Eur J Biochem 1991, 195:377-83.
66. Te-Chung Liu: Biochemical and Biophysical Research communication
2000, 274:811-816.
67. Parmar S, Platanias LC: Interferons: mechanisms of action and
clinical applications.  Curr Opin Oncol 2003, 15:431-439.
68. Brassard DL, Grace MJ, Bordens RW: Interferon-alpha as an
immunotherapeutic protein.  J Leukoc Biol 2002, 71:565-81.
69. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY: Analysis of gene
expression profiles in human systemic lupus erythematosus
using oligonucleotide microarray.  Genes Immun 2003, 4:177-86.
70. Chill JH, Quadt SR, Levy R, Schreiber G, Anglister J: The human
type I interferon receptor: NMR structure reveals the
molecular basis of ligand binding.  Structure (Camb) 2003,
11:791-802.
71. Roisman LC, Piehler J, Trosset JY, Scheraga HA, Schreiber G: Struc-
ture of the interferon-receptor complex determined by dis-
tance constraints from double-mutant cycles and flexible
docking.  Proc Natl Acad Sci U S A 2001, 98:13231-13236.